<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Gastroenterology: IBD &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/ibd/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>PPI best for preventing GI bleeding in patients with ACS or STEMI</title>
		<link>http://www.thedoctorschannel.com/view/ppi-best-for-preventing-gi-bleeding-in-patients-with-acs-or-stemi/</link>
		<pubDate>Fri, 02 Dec 2011 17:49:00 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[critical care]]></category>
		<category><![CDATA[esomeprazole]]></category>
		<category><![CDATA[famotidine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[GI bleeding]]></category>
		<category><![CDATA[hospitalist]]></category>
		<category><![CDATA[PPI]]></category>
		<category><![CDATA[STEMI]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/ppi-best-for-preventing-gi-bleeding-in-patients-with-acs-or-stemi/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In patients with acute coronary syndrome (ACS) or ST-elevation myocardial infarction (STEMI), the proton pump inhibitor (PPI) esomeprazole is superior to the H2-receptor antagonist (H2RA) famotidine for the prevention of gastrointestinal bleeding related to combination antiplatelet and anticoagulant therapy, a new study shows. ACS or STEMI patients are now routinely -]]></description>
		
			<media:content duration="1:12" medium="video">
		<media:title><![CDATA[PPI best for preventing GI bleeding in patients with ACS or STEMI]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In patients with acute coronary syndrome (ACS) or ST-elevation myocardial infarction (STEMI), the proton pump inhibitor (PPI) esomeprazole is superior to the H2-receptor antagonist (H2RA) famotidine for the prevention of gastrointestinal bleeding related to combination antiplatelet and anticoagulant therapy, a new study shows. ACS or STEMI patients are now routinely -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/ppi-best-for-preventing-gi-bleeding-in-patients-with-acs-or-stemi/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4903.jpg"/>
	<media:keywords><![CDATA[ACS,Cardiology,critical care,esomeprazole,famotidine,Gastroenterology,GI bleeding,hospitalist,Internal Medicine,PPI,STEMI]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Risk of VTEs increased during inflammatory bowel disease flares</title>
		<link>http://www.thedoctorschannel.com/view/risk-of-vtes-increased-during-inflammatory-bowel-disease-flares-2/</link>
		<pubDate>Tue, 22 Mar 2011 18:37:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Americal Journal of Gastroenterology]]></category>
		<category><![CDATA[Dr. Geoffrey C. Nguyen]]></category>
		<category><![CDATA[Dr. Sanjay K. Murthy]]></category>
		<category><![CDATA[IBD]]></category>
		<category><![CDATA[Inflammatory bowel disease]]></category>
		<category><![CDATA[venous thromboembolic events]]></category>
		<category><![CDATA[VTEs]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/risk-of-vtes-increased-during-inflammatory-bowel-disease-flares-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Inflammatory bowel disease (IBD) activity is an independent risk factor for the development of venous thromboembolic events (VTEs). That’s one of the findings of an epidemiological review published in the Americal Journal of Gastroenterology online March 15. Dr. Sanjay K. Murthy and Dr. Geoffrey C. Nguyen, with Mount Sinai Hospital, -]]></description>
		
			<media:content duration="2:01" medium="video">
		<media:title><![CDATA[Risk of VTEs increased during inflammatory bowel disease flares]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Inflammatory bowel disease (IBD) activity is an independent risk factor for the development of venous thromboembolic events (VTEs). That’s one of the findings of an epidemiological review published in the Americal Journal of Gastroenterology online March 15. Dr. Sanjay K. Murthy and Dr. Geoffrey C. Nguyen, with Mount Sinai Hospital, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/risk-of-vtes-increased-during-inflammatory-bowel-disease-flares-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4188.jpg"/>
	<media:keywords><![CDATA[Americal Journal of Gastroenterology,Dr. Geoffrey C. Nguyen,Dr. Sanjay K. Murthy,IBD,Inflammatory bowel disease,venous thromboembolic events,VTEs]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Double-balloon endoscopy better for visualizing small intestine</title>
		<link>http://www.thedoctorschannel.com/view/double-balloon-endoscopy-better-for-visualizing-small-intestine-2/</link>
		<pubDate>Sat, 05 Feb 2011 02:22:00 +0000</pubDate> 
				<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[DBE]]></category>
		<category><![CDATA[double-balloon endoscopy]]></category>
		<category><![CDATA[Dr. Hirotsugu Watabe]]></category>
		<category><![CDATA[Gastrointestinal Endoscopy]]></category>
		<category><![CDATA[SBE]]></category>
		<category><![CDATA[single-balloon endoscopy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/double-balloon-endoscopy-better-for-visualizing-small-intestine-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Complete visualization of the entire small intestine is achieved more easily with double-balloon endoscopy than with single-balloon endoscopy, according to a report from Japan appearing in Gastrointestinal Endoscopy online January 27. The authors explain that double-balloon endoscopy (DBE) allows access to the small intestine. Inflating and deflating the balloons &#8212; -]]></description>
		
			<media:content duration="1:34" medium="video">
		<media:title><![CDATA[Double-balloon endoscopy better for visualizing small intestine]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Complete visualization of the entire small intestine is achieved more easily with double-balloon endoscopy than with single-balloon endoscopy, according to a report from Japan appearing in Gastrointestinal Endoscopy online January 27. The authors explain that double-balloon endoscopy (DBE) allows access to the small intestine. Inflating and deflating the balloons &#8212; -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/double-balloon-endoscopy-better-for-visualizing-small-intestine-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/4062.jpg"/>
	<media:keywords><![CDATA[DBE,double-balloon endoscopy,Dr. Hirotsugu Watabe,Gastrointestinal Endoscopy,SBE,single-balloon endoscopy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Can 5-ASAs Prevent Crohn&#8217;s Relapse After Surgery?</title>
		<link>http://www.thedoctorschannel.com/view/can-5-asas-prevent-crohns-relapse-after-surgery-2/</link>
		<pubDate>Wed, 25 Aug 2010 23:28:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[American Journal of Gastroenterology]]></category>
		<category><![CDATA[Crohn's]]></category>
		<category><![CDATA[Dr. Alexander C. Ford]]></category>
		<category><![CDATA[mesalamine]]></category>
		<category><![CDATA[surgery]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/can-5-asas-prevent-crohns-relapse-after-surgery-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; After surgically induced remission of Crohn’s disease, treatment with mesalamine reduces the risk of relapse somewhat; sulfasalazine, however, has no apparent benefit, according the results of a meta-analysis. Reporting in the American Journal of Gastroenterology published online August 17, Dr. Alexander C. Ford with Leeds General Infirmary, UK, and colleagues -]]></description>
		
			<media:content duration="1:26" medium="video">
		<media:title><![CDATA[Can 5-ASAs Prevent Crohn&#8217;s Relapse After Surgery?]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; After surgically induced remission of Crohn’s disease, treatment with mesalamine reduces the risk of relapse somewhat; sulfasalazine, however, has no apparent benefit, according the results of a meta-analysis. Reporting in the American Journal of Gastroenterology published online August 17, Dr. Alexander C. Ford with Leeds General Infirmary, UK, and colleagues -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/can-5-asas-prevent-crohns-relapse-after-surgery-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3590.jpg"/>
	<media:keywords><![CDATA[American Journal of Gastroenterology,Crohn's,Dr. Alexander C. Ford,mesalamine,surgery]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>High-potency probiotic mix has benefits in relapsing ulcerative colitis</title>
		<link>http://www.thedoctorschannel.com/view/high-potency-probiotic-mix-has-benefits-in-relapsing-ulcerative-colitis-2/</link>
		<pubDate>Fri, 11 Jun 2010 17:50:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Patient Education]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[immunosuppressive therapy]]></category>
		<category><![CDATA[probiotic]]></category>
		<category><![CDATA[Relapse]]></category>
		<category><![CDATA[UC]]></category>
		<category><![CDATA[ulcerative colitis]]></category>
		<category><![CDATA[VSL#3]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/high-potency-probiotic-mix-has-benefits-in-relapsing-ulcerative-colitis-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Patients with relapsing mild-to-moderate ulcerative colitis (UC) on immunosuppressive therapy may benefit from the addition of a high-potency probiotic mixture (VSL#3; VSL Pharmaceuticals Inc., Towson, Maryland), results of a randomized trial suggest. Probiotic supplementation with VSL#3 &#8220;improves the clinical picture in patients suffering from UC and may avoid a new -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[High-potency probiotic mix has benefits in relapsing ulcerative colitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Patients with relapsing mild-to-moderate ulcerative colitis (UC) on immunosuppressive therapy may benefit from the addition of a high-potency probiotic mixture (VSL#3; VSL Pharmaceuticals Inc., Towson, Maryland), results of a randomized trial suggest. Probiotic supplementation with VSL#3 &#8220;improves the clinical picture in patients suffering from UC and may avoid a new -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/high-potency-probiotic-mix-has-benefits-in-relapsing-ulcerative-colitis-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3334.jpg"/>
	<media:keywords><![CDATA[immunosuppressive therapy,probiotic,Relapse,UC,ulcerative colitis,VSL#3]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Benefits of probiotics in preterm neonates confirmed: studies</title>
		<link>http://www.thedoctorschannel.com/view/benefits-of-probiotics-in-preterm-neonates-confirmed-studies-2/</link>
		<pubDate>Thu, 22 Apr 2010 18:37:00 +0000</pubDate> 
				<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[NEC]]></category>
		<category><![CDATA[necrotizing enterocolitis]]></category>
		<category><![CDATA[preterm neonates]]></category>
		<category><![CDATA[probiotic supplements]]></category>
		<category><![CDATA[very low birth weight]]></category>
		<category><![CDATA[VLBW]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/benefits-of-probiotics-in-preterm-neonates-confirmed-studies-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The &#8220;dramatic benefits&#8221; of probiotic supplements for reducing death and necrotizing enterocolitis (NEC) in very low birth weight (VLBW) preterm neonates have been confirmed by a meta-analysis published online today in Pediatrics, the study authors say. &#8220;Given the totality of the evidence, additional placebo-controlled trials are unnecessary if a suitable -]]></description>
		
			<media:content duration="1:49" medium="video">
		<media:title><![CDATA[Benefits of probiotics in preterm neonates confirmed: studies]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The &#8220;dramatic benefits&#8221; of probiotic supplements for reducing death and necrotizing enterocolitis (NEC) in very low birth weight (VLBW) preterm neonates have been confirmed by a meta-analysis published online today in Pediatrics, the study authors say. &#8220;Given the totality of the evidence, additional placebo-controlled trials are unnecessary if a suitable -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/benefits-of-probiotics-in-preterm-neonates-confirmed-studies-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3161.jpg"/>
	<media:keywords><![CDATA[NEC,necrotizing enterocolitis,preterm neonates,probiotic supplements,very low birth weight,VLBW]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Infliximab plus azathioprine effective for stubborn Crohn&#8217;s disease</title>
		<link>http://www.thedoctorschannel.com/view/infliximab-plus-azathioprine-effective-for-stubborn-crohns-disease-2/</link>
		<pubDate>Fri, 16 Apr 2010 20:44:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Patient Education]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[azothioprine]]></category>
		<category><![CDATA[crohn's disease]]></category>
		<category><![CDATA[infliximab]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/infliximab-plus-azathioprine-effective-for-stubborn-crohns-disease-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; In adults with moderate-to-severe active Crohn&#8217;s disease, treatment with infliximab plus azathioprine, or infliximab alone, led to significantly higher rates of corticosteroid-free clinical remission and mucosal healing than treatment with azathioprine alone. “The development of infliximab has been a major advance in the management of Crohn’s disease (CD), yet many -]]></description>
		
			<media:content duration="2:18" medium="video">
		<media:title><![CDATA[Infliximab plus azathioprine effective for stubborn Crohn&#8217;s disease]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; In adults with moderate-to-severe active Crohn&#8217;s disease, treatment with infliximab plus azathioprine, or infliximab alone, led to significantly higher rates of corticosteroid-free clinical remission and mucosal healing than treatment with azathioprine alone. “The development of infliximab has been a major advance in the management of Crohn’s disease (CD), yet many -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/infliximab-plus-azathioprine-effective-for-stubborn-crohns-disease-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3142.jpg"/>
	<media:keywords><![CDATA[azothioprine,crohn's disease,infliximab]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Prophylactic antibiotics may cut mortality in burn patients</title>
		<link>http://www.thedoctorschannel.com/view/prophylactic-antibiotics-may-cut-mortality-in-burn-patients-2/</link>
		<pubDate>Fri, 26 Feb 2010 21:17:00 +0000</pubDate> 
				<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Emergency Medicine]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Public Health & Prevention]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[burn patients]]></category>
		<category><![CDATA[prophylactic antibiotics]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/prophylactic-antibiotics-may-cut-mortality-in-burn-patients-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Prophylactic antibiotics may improve survival of burn patients, a meta-analysis suggests, although the authors acknowledge that the quality of the supporting data is weak. A number of factors increase the risk of infection in burn patients, yet “there is a broad and uniform consensus in the current literature that prophylaxis -]]></description>
		
			<media:content duration="1:53" medium="video">
		<media:title><![CDATA[Prophylactic antibiotics may cut mortality in burn patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Prophylactic antibiotics may improve survival of burn patients, a meta-analysis suggests, although the authors acknowledge that the quality of the supporting data is weak. A number of factors increase the risk of infection in burn patients, yet “there is a broad and uniform consensus in the current literature that prophylaxis -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/prophylactic-antibiotics-may-cut-mortality-in-burn-patients-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/2968.jpg"/>
	<media:keywords><![CDATA[burn patients,prophylactic antibiotics]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Long-term antibiotic treatment effective for Crohn&#8217;s disease</title>
		<link>http://www.thedoctorschannel.com/view/long-term-antibiotic-treatment-effective-for-crohns-disease-2/</link>
		<pubDate>Tue, 09 Feb 2010 01:01:00 +0000</pubDate> 
				<category><![CDATA[Allergy & Clinical Immunology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[clofazimine]]></category>
		<category><![CDATA[crohn's disease]]></category>
		<category><![CDATA[Dr. Martin Feller]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[nitroimidazoles]]></category>
		<category><![CDATA[Reuters]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/long-term-antibiotic-treatment-effective-for-crohns-disease-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Long-term treatment with clofazimine or nitroimidazoles may help control Crohn&#8217;s disease, according to the authors of a systematic review and meta-analysis. Several bacteria have been implicated in Crohn&#8217;s disease, but antibiotics are currently recommended only for certain complications, such as sepsis or perianal disease, the researchers note in the February -]]></description>
		
			<media:content duration="1:40" medium="video">
		<media:title><![CDATA[Long-term antibiotic treatment effective for Crohn&#8217;s disease]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Long-term treatment with clofazimine or nitroimidazoles may help control Crohn&#8217;s disease, according to the authors of a systematic review and meta-analysis. Several bacteria have been implicated in Crohn&#8217;s disease, but antibiotics are currently recommended only for certain complications, such as sepsis or perianal disease, the researchers note in the February -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/long-term-antibiotic-treatment-effective-for-crohns-disease-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/2905.jpg"/>
	<media:keywords><![CDATA[antibiotics,clofazimine,crohn's disease,Dr. Martin Feller,health,infectious diseases,nitroimidazoles,Reuters]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Thiopurines for IBD raise risk of lymphoproliferative disorders</title>
		<link>http://www.thedoctorschannel.com/view/thiopurines-for-ibd-raise-risk-of-lymphoproliferative-disorders-2/</link>
		<pubDate>Thu, 22 Oct 2009 17:53:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Gastroenterology: IBD]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[6-mercaptopurine]]></category>
		<category><![CDATA[azathiprine]]></category>
		<category><![CDATA[IBD]]></category>
		<category><![CDATA[Inflammatory bowel disease]]></category>
		<category><![CDATA[lymphoproliferative disorder]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/thiopurines-for-ibd-raise-risk-of-lymphoproliferative-disorders-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Patients taking azathioprine or 6-mercaptopurine for inflammatory bowel disease (IBD) have more than a five-times higher risk of developing a lymphoproliferative disorder compared to IBD patients not receiving thiopurines, researchers from France reported Monday in The Lancet. &#8220;The frank excess risk&#8221; of malignant lymphomas is due to a lack of -]]></description>
		
			<media:content duration="2:36" medium="video">
		<media:title><![CDATA[Thiopurines for IBD raise risk of lymphoproliferative disorders]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Patients taking azathioprine or 6-mercaptopurine for inflammatory bowel disease (IBD) have more than a five-times higher risk of developing a lymphoproliferative disorder compared to IBD patients not receiving thiopurines, researchers from France reported Monday in The Lancet. &#8220;The frank excess risk&#8221; of malignant lymphomas is due to a lack of -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/thiopurines-for-ibd-raise-risk-of-lymphoproliferative-disorders-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/03/2536-full.jpg"/>
	<media:keywords><![CDATA[6-mercaptopurine,azathiprine,IBD,Inflammatory bowel disease,lymphoproliferative disorder]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
